A safety, tolerability, and pharmacokinetic study of single and multiple ascending doses of LY3322207 in healthy subjects and subjects with hypertension on ACE I/ARB therapy.
Completed
- Conditions
- 10019280Chronic heart failure
- Registration Number
- NL-OMON45832
- Lead Sponsor
- Eli Lilly
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 88
Inclusion Criteria
healthy male or female (sterilized or post-menopausal)
18 - 65 jaar age
BMI 18.0 - 30.0 kilograms/meter2
non smokers
Exclusion Criteria
Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>(Part A - SAD)<br /><br>To evaluate safety and tolerability of LY3322207 in healthy subjects following<br /><br>a single SC dose.<br /><br>(Part B - MAD)<br /><br>To evaluate safety and tolerability of LY3322207 in healthy subjects following<br /><br>multiple SC doses.<br /><br>(Part C)<br /><br>To evaluate safety and tolerability of LY3322207 in subjects with hypertension<br /><br>(on ACE-I/ARB therapy).</p><br>
- Secondary Outcome Measures
Name Time Method